|Articles|July 1, 2006

LCGC Supplements

  • Special Issues-07-01-2006
  • Volume 0
  • Issue 0

Moving Biotech Products from CBER to CDER: A Work in Progress

A slow, steady process of transitioning biologicals has allayed industry concerns.
External Link - article-416324.pdf

Articles in this issue

over 19 years ago

Analytical Instrument Qualification

over 19 years ago

GMP and Phase I Clinical Trials: Streamlining the Critical Path?

over 19 years ago

Team Effort

over 19 years ago

Rated PG: Pharmaceutical Guidance Suggested

over 19 years ago

European Clinical Trial Regulations Undergo a Slow Revolution

over 19 years ago

A Practical and Cost-Effective Risk Assessment for the Validation of Commercial Laboratory Computerized Systems

over 19 years ago

FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chief

over 19 years ago

New Climate

over 19 years ago

2006: A Regulatory Odyssey

over 19 years ago

CDER?s Division of Post-Marketing Evaluation for Quality Assessment

Newsletter

Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.

Subscribe Now!

Related Content